Skip to main content
S&P 5007,722.60+0.60%DOW52,377.57+0.03%NASDAQ26,477.81+1.18%BTC$80,673.00+1.06%ETH$2,343.28+1.29%GOLD$4,074.50+0.89%OIL$99.92-1.81%
Smart Investors Daily
SID Premium
DT

NASDAQ · DTIL

Precision BioSciences, Inc.

Healthcare · Biotechnology

$6.41

Up+$0.38 (+5.93%)

Updated Oct 27, 2026, 8:09 PM

SID Score

5.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
64.95M
P/E ratio
-0.69
Dividend yield
0.00%
52-week range
$3.53 – $9.62
Volume
266.68K
Avg. volume
180.03K

Price performance · DTIL

DTIL price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 26, 2026

DTIL closed at $6.41 after 21 trading sessions, up 2.72% for the selected period.

Last close
$6.41
Period change
+2.72%
Period low
$5.77
Period high
$6.78
Daily close
View OHLC price history
DTIL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 26, 2026$6.68$6.8763$6.37$6.41266.68K
Oct 23, 2026$6.73$6.73$6.29$6.64275.53K
Oct 22, 2026$6.70$6.925$6.58$6.78132.43K
Oct 21, 2026$6.62$6.86$6.545$6.71231.04K
Oct 20, 2026$6.09$6.67$6.09$6.56213.66K
Oct 19, 2026$5.80$6.21$5.77$6.19176.47K
Oct 16, 2026$6.18$6.18$5.72$5.77300.25K
Oct 15, 2026$6.04$6.20$5.98$6.17246.14K
Oct 14, 2026$6.05$6.25$5.92$6.03294.25K
Oct 13, 2026$6.51$6.55$6.05$6.10326.68K
Oct 12, 2026$6.71$6.7294$6.4482$6.53228.78K
Oct 9, 2026$6.43$6.92$6.35$6.72263.69K
Oct 8, 2026$6.25$6.53$6.19$6.43332.55K
Oct 7, 2026$6.20$6.38$6.11$6.25162.52K
Oct 6, 2026$6.36$6.40$6.105$6.20190.96K
Oct 5, 2026$6.36$6.375$5.975$6.31219.03K
Oct 2, 2026$6.42$6.44$6.20$6.31292.95K
Oct 1, 2026$6.33$6.47$6.24$6.33242.17K
Sep 30, 2026$6.24$6.40$6.14$6.26249.25K
Sep 29, 2026$6.37$6.45$6.08$6.18154.22K
Sep 28, 2026$6.21$6.255$6.00$6.24222.82K

Latest DTIL news

The latest Smart Investors Daily articles mentioning DTIL.

Stock researchCompany · Overview

DTIL research

Overview

Company profile and research snapshot.

Company profile

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$15.50
Implied upside
—
Analysts
10
DTIL recent ratings
DateFirmRatingTarget
Aug 3, 2026HC Wainwright & Co.Buy—
Jul 9, 2026HC Wainwright & Co.Buy—
Jun 9, 2026OppenheimerOutperform—
May 27, 2026HC Wainwright & Co.Buy—
May 21, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 8, 2026

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026

DURHAM, N.C., October 08, 2026--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has been selected to deliver a late-breaking oral presentation at The Liver Meeting 2026, the 77th annual meeting of the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting 2026 will take place November 5-9 in Denv

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By